Advertisement

Pharmaceutical Medicine

, Volume 25, Issue 6, pp 405–414 | Cite as

Forum

Update

Contents

  • 1. UK Government to Pursue its Value-Based Pricing System

  • 2. Break in the Silence around FDAMA Section 114

  • 3. Genetic Testing: a Powerful Cost-Saving Tool

  • 4. New Advisory Council Created for the Australian National Preventive Health Agency

  • 5. France Unveils Plans to Overhaul Drug Regulatory System

  • 6. India’s Clinical Trial Deaths Total 1725 in Last 4 Years

  • 7. UK NHS gets NICE Advice on Medicine Adherence

  • 8. Affordability of Rx Drugs Similar in Canada and the US

  • 9. Scottish Government Unveils Plan to Improve Cancer Survival Rates

  • 10. Australia Finalises Historic Health Reforms

  • 11. Regenerative Medicine Revenue Expected to Reach $US8.84 billion in 2021

  • 12. Spending on Public Health a “Wise” Investment

  • 13. Vitamin K Antagonists Linked to Coronary Calcification in AF Patients

  • 14. Sulfonylureas Increase Cancer Risk

  • 15. Antipsychotics Increase Hip Fracture and Pneumonia in the Elderly

  • 16. Methylene Blue, Linezolid: Serious Interactions with Psych Meds

  • 17. News from EACPT

  • 18. News...

References

Reference

  1. Department of Health. Government’s response to the consultation — A new valuebased approach to the pricing of branded medicines. 2011 Jul 18 [online]. Available from URL: http://www.dh.gov.uk/s [Accessed 2011 Sept 14]

References

  1. 1.
    Neumann PJ, Lin P-J, Hughes TE. USFDA Modernization Act, Section 114: uses, opportunities and implications for comparative effectiveness research. Pharmacoeconomics 2011; 29 (8): 687–92PubMedCrossRefGoogle Scholar
  2. 2.
    Vernon JA, Golec JH. The case for less, not more, US FDA regulation. Pharmacoeconomics 2011; 29 (8): 637–40PubMedCrossRefGoogle Scholar

Reference

  1. American Clinical Laboratory Association. Genetic testing can help the US cut costs and improve health care [media release]. 2011 Jul 25 [online]. Available from URL: http://www.clinical-labs.org [Accessed 2011 Sept 14]

Reference

  1. Department of Health and Aging. New advisory council to boost disease prevention efforts [media release]. 2011 Jul 18 [online]. Available from URL: http://www.health.gov.au [Accessed 2011 Sept 14]

Reference

  1. Arie S. France is set to radically overhaul its drug regulatory system. BMJ 2011; 343: d4979PubMedCrossRefGoogle Scholar

Reference

  1. Tandon A. Indians sitting ducks as drug trials turn fatal. 2011 Aug 7 [online]. Available from URL: http://www.tribuneindia.com [Accessed 2011 Sept 14]Google Scholar

Reference

  1. National Institute for Health and Clinical Excellence. NICE advice could help in drive to cut medicines wastage. 2011 Aug 8 [online]. Available from URL: http://www.nice.org.uk [Accessed 2011 Sept 14]

Reference

  1. Skinner BJ, Rovere M. Average personal affordability of prescription drug spending in Canada and the United States. 2011 Jul 21 [online]. Available from URL: http://www.fraserinstitute.org [Accessed 2011 Sept 14]Google Scholar

Reference

  1. NHS National Services Scotland. Plan launched to detect cancer earlier [media release]. 2011 Aug 1 [online]. Available from URL: http://www.scotland.gov.uk [Accessed 2011 Sept 14]

Reference

  1. Ministry of Health. National health reform finalised [media release]. 2011 Aug 2 [online]. Available from URL: http://www.health.gov.au [Accessed 2011 Sept 14]

Reference

  1. Visiongain. The world regenerative medicine revenues will reach $8.84bn in 2021 says brand new visiongain report [media release]. 2011 Jul 28 [online]. Available from URL: http://www.visiongain.com [Accessed 2011 Sept 14]

Reference

  1. Mays GP, Smith SA. Evidence links increases in public health spending to declines in preventable deaths. Health Aff 2011; 30 (8): 1585–93CrossRefGoogle Scholar

Reference

  1. Weijs B, Blaauw Y, Rennenberg RJ, et al. Patients using vitaminKantagonists show increased levels of coronary calcification: an observational study in low-risk atrial fibrillation patients. Eur Heart J 2011; doi: 10.1093/eurheartj/ehr226.Google Scholar

Reference

  1. Sun G, Wells B, Zimmerman R, et al. Increased cancer risk with sulfonylureas vs metformin in womenwith diabetes: an observational cohort study [abstract no. 1350-P]. 71st Annual Scientific Sessions of the American Diabetes Association; 2011 Jun 24–28; San Diego [online]. Available from URL: http://professional.diabetes.org [Accessed 2011 Sept 14]Google Scholar

Reference

  1. Pratt N, Roughead EE, Ramsay E, et al. Risk of hospitalization for hip fracture and pneumonia associated with antipsychotic prescribing in the elderly: a self-controlled caseseries analysis in an Australian health care claims database. Drug Saf 2011; 34 (7): 567–75PubMedCrossRefGoogle Scholar

References

  1. 1.
    Food and Drug Administration. FDA drug safety communication: serious CNS reactions possible when methylene blue is given to patients taking certain psychiatric medications. 2011 Jul 26 [online]. Available from URL: http://www.fda.gov [Accessed 2011 Sept 14]
  2. 2.
    Food and Drug Administration. FDA drug safety communication: serious CNS reactions possible when linezolid (Zyvox) is given to patients taking certain psychiatric medications. 2011 Jul 26 [online]. Available from URL: http://www.fda.gov [Accessed 2011 Sept 14]

References

  1. 1.
    Andersson ML, Björkhem-Bergman L, Lindh JD. Possible drug-drug interaction between quetiapine and lamotrigine: evidence from a Swedish therapeutic drug monitoring database [abstract no. O58]. 10th Congress of the European Association for Clinical Pharmacology and Therapeutics; 2011 Jun 26–29; Budapest [online]. Available from URL: http://onlinelibrary.wiley.com/doi/10.1111/pto.2011.109.issue-s1/issuetoc [Accessed 2011 Sept 19]Google Scholar
  2. 2.
    Kukes IV, Sychev DA. Analysis of frequency and structure of adverse reactions from oral anticoagulants, recorded by spontaneous reporting in Russia [abstract no. P64]. 10th Congress of the European Association for Clinical Pharmacology and Therapeutics; 2011 Jun 26–29; Budapest [online]. Available from URL: http://onlinelibrary.wiley.com/doi/10.1111/pto.2011.109.issue-s1/issuetoc [Accessed 2011 Sept 19]Google Scholar
  3. 3.
    Ing Lorenzini KR, L’huillier AG, Crisinel PA, et al. ABCB1 gene polymorphisms and neuropsychiatric adverse events in oseltamivir-treated children during influenza H1N1/09 pandemia [abstract no. P225]. 10th Congress of the European Association for Clinical Pharmacology and Therapeutics; 2011 Jun 26–29; Budapest [online]. Available from URL: http://onlinelibrary.wiley.com/doi/10.1111/pto.2011.109.issue-s1/issuetoc [Accessed 2011 Sept 19]Google Scholar
  4. 4.
    Saddichha S, Akhtar S. Prehypertension, hypertension and cardiometabolic changes associated with antipsychotic use in schizophrenia [abstract no. O33]. 10th Congress of the European Association for Clinical Pharmacology and Therapeutics; 2011 Jun 26–29; Budapest [online]. Available from URL: http://onlinelibrary.wiley.com/doi/10.1111/pto.2011.109.issue-s1/issuetoc [Accessed 2011 Sept 19]Google Scholar

References

  1. 1.
    Lehe J, Wayda B, Quevedo J, et al. Impact of point-of-care CD4 testing on antiretroviral therapy scale-up and patient treatment costs in resource-limited settings [abstract no. TULBPE065]. 6th International AIDS Society Conference on HIV Pathogenesis and Treatment; 2011 Jul 17–20; Rome [online]. Available from URL: http://www.ias2011.org [Accessed 2011 Sept 19]Google Scholar
  2. 2.
    Ishikawa N, Shimbo T, Wi T, et al. Cost-effectiveness of universal antenatal HIV testing and PMTCT services in low and concentrated epidemics: moving towards the elimination of new paediatric HIV infections in Asia-Pacific [abstract no. CDD123]. 6th International AIDS Society Conference on HIV Pathogenesis and Treatment; 2011 Jul 17–20; Rome [online]. Available from URL: http://www.ias2011.org [Accessed 2011 Sept 19]Google Scholar
  3. 3.
    Metsch LR, Colfax GN, Leff JA, et al. The cost-effectiveness of on-site rapid HIV testing in substance abuse treatment: results of the CTN 0032 randomized trial [abstract no. MOAD0104]. 6th International AIDS Society Conference on HIV Pathogenesis and Treatment; 2011 Jul 17–20; Rome [online]. Available from URL: http://www.ias2011.org [Accessed 2011 Sept 19]Google Scholar
  4. 4.
    McCarthy E, Ipuge Y, Silaa R, et al. Money spent on prevention of mother-tochild transmission: a good investment for Tanzania [abstract no. MOPE434]. 6th International AIDS Society Conference on HIV Pathogenesis and Treatment; 2011 Jul 17–20; Rome [online]. Available from URL: http://www.ias2011.org [Accessed 2011 Sept 19]Google Scholar
  5. 5.
    McCarthy E, Ipuge Y, Silaa R, et al. What will it cost to move from the 2006 to 2010 WHO pediatric antiretroviral guidelines in Tanzania? [abstract no. MOPE458]. 6th International AIDS Society Conference on HIV Pathogenesis and Treatment; 2011 Jul 17–20; Rome [online].Available from URL: http://www.ias2011.org [Accessed 2011 Sept 19]Google Scholar
  6. 6.
    McCarthy E, Ipuge Y, Silaa R, et al. Cost-effectiveness of options A and B of the 2010 WHO PMTCT antiretroviral guidelines in Tanzania [abstract no. TUPE419]. 6th International AIDS Society Conference on HIV Pathogenesis and Treatment; 2011 Jul 17–20; Rome [online]. Available from URL: http://www.ias2011.org [Accessed 2011 Sept 19]Google Scholar

References

  1. 1.
    Li SC, Woerdenbag HJ, Coyte P, et al. Cost-effectiveness of rotavirus immunization in Vietnam: results and challenges [abstract no N/A]. 8th World Congress of the International Health Economics Association: Transforming Health and Economics; 2011 Jul 10–13; Toronto [online]. Available from URL: http://www.healtheconomics.org [Accessed 2011 Sept 19]Google Scholar
  2. 2.
    Aballéa S, Vossius C, Guelfucci F, et al. Cost-effectiveness of rasagiline monotherapy aimed at disease modulation in patients with parkinson’s disease in Norway [abstract no N/A]. 8th World Congress of the International Health Economics Association: Transforming Health and Economics; 2011 Jul 10–13; Toronto [online]. Available from URL: http://www.healtheconomics.org [Accessed 2011 Sept 19]Google Scholar
  3. 3.
    Jaramillo HEC. The cost-effectiveness of enzyme replacement therapy (ERT) for infantile Pompe’s disease: comparative perspective from a high income country (England) and a middle income one (Colombia) [abstract no. N/A]. 8th World Congress of the International Health Economics Association: Transforming Health and Economics; 2011 Jul 10–13; Toronto [online]. Available from URL: http://www.healtheconomics.org [Accessed 2011 Sept 19]Google Scholar
  4. 4.
    Wong IOL, Cowling BJ, Leung GM. Cost effectiveness of breast cancer-related interventions among Chinese women in Hong Kong [abstract no N/A]. 8th World Congress of the International Health Economics Association: Transforming Health and Economics; 2011 Jul 10–13; Toronto [online]. Available from URL: http://www.healtheconomics.org [Accessed 2011 Sept 19]Google Scholar
  5. 5.
    Brown A. The cost-effectiveness of clopidogrel and other antiplatelet agents for the secondary prevention of vascular events in adults with acute coronary syndrome or peripheral vascular disease [abstract no N/A]. 8th World Congress of the International Health Economics Association: Transforming Health and Economics; 2011 Jul 10–13; Toronto [online]. Available from URL: http://www.healtheconomics.org [Accessed 2011 Sept 19]Google Scholar
  6. 6.
    Connelly L, Le HDN. The cost-effectiveness of a bivalent human papillomavirus vaccination program in Japan [abstract no TO-P804]. 8th World Congress of the International Health Economics Association: Transforming Health and Economics; 2011 Jul 10–13; Toronto [online]. Available from URL: http://www.healtheconomics.org [Accessed 2011 Sept 19]Google Scholar

Copyright information

© Adis Data Information BV 2011

Personalised recommendations